Cbre Investment Management Listed Real Assets LLC Sells 105,451 Shares of Healthpeak Properties, Inc. $DOC

Cbre Investment Management Listed Real Assets LLC cut its position in Healthpeak Properties, Inc. (NYSE:DOC) by 1.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 5,696,889 shares of the real estate investment trust’s stock after selling 105,451 shares during the period. Cbre Investment Management Listed Real Assets LLC’s holdings in Healthpeak Properties were worth $91,606,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Healthpeak Properties by 7.0% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,935,397 shares of the real estate investment trust’s stock valued at $37,063,000 after buying an additional 126,322 shares during the period. JPMorgan Chase & Co. boosted its stake in Healthpeak Properties by 41.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 28,236,534 shares of the real estate investment trust’s stock worth $540,730,000 after purchasing an additional 8,212,504 shares during the period. Envestnet Asset Management Inc. boosted its stake in Healthpeak Properties by 30.3% in the 3rd quarter. Envestnet Asset Management Inc. now owns 3,906,824 shares of the real estate investment trust’s stock worth $74,816,000 after purchasing an additional 907,509 shares during the period. Handelsbanken Fonder AB boosted its stake in Healthpeak Properties by 48.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 238,700 shares of the real estate investment trust’s stock worth $4,571,000 after purchasing an additional 78,200 shares during the period. Finally, Northside Capital Management LLC boosted its stake in Healthpeak Properties by 47.7% in the 4th quarter. Northside Capital Management LLC now owns 472,337 shares of the real estate investment trust’s stock worth $7,595,000 after purchasing an additional 152,579 shares during the period. 93.57% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on DOC shares. Royal Bank Of Canada raised their target price on Healthpeak Properties from $20.00 to $21.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Wells Fargo & Company raised their target price on Healthpeak Properties from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Monday. UBS Group raised their target price on Healthpeak Properties from $17.00 to $19.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 13th. Evercore downgraded Healthpeak Properties from an “outperform” rating to an “in-line” rating and set a $21.00 target price for the company. in a research note on Monday, May 11th. Finally, Morgan Stanley raised their target price on Healthpeak Properties from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, May 22nd. Four research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $19.38.

Healthpeak Properties Trading Down 0.8%

Shares of DOC stock opened at $19.01 on Tuesday. The stock has a market capitalization of $13.10 billion, a PE ratio of 59.40, a P/E/G ratio of 2.43 and a beta of 1.05. Healthpeak Properties, Inc. has a 1-year low of $15.70 and a 1-year high of $20.27. The business has a 50-day moving average of $17.76 and a 200 day moving average of $17.33. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.96 and a quick ratio of 2.96.

Healthpeak Properties (NYSE:DOC) last issued its earnings results on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.02. The company had revenue of $752.95 million during the quarter, compared to analysts’ expectations of $694.59 million. Healthpeak Properties had a return on equity of 2.61% and a net margin of 7.73%.Healthpeak Properties’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.46 EPS. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. As a group, sell-side analysts anticipate that Healthpeak Properties, Inc. will post 1.75 earnings per share for the current year.

Healthpeak Properties Dividend Announcement

The business also recently announced a monthly dividend, which will be paid on Friday, June 26th. Investors of record on Monday, June 15th will be issued a dividend of $0.1017 per share. The ex-dividend date is Monday, June 15th. This represents a c) annualized dividend and a yield of 6.4%. Healthpeak Properties’s dividend payout ratio is currently 381.25%.

Insiders Place Their Bets

In related news, insider Scott R. Bohn sold 10,989 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total transaction of $213,736.05. Following the completion of the sale, the insider directly owned 7,636 shares in the company, valued at $148,520.20. This represents a 59.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.23% of the stock is owned by corporate insiders.

About Healthpeak Properties

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.